Publications

Joseph NM, Umetsu SE, Kim GE, Terry M, Perry A, Bergsland E, Kakar S. Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53. Endocrine pathology. 2024. PMID: 39556303

Morrow WP, Milligan NS, Ohgami RS, Young KH, Wang B, Vega F, Marques-Piubelli ML, Feldman AL, Slack GW, Savage KJ, Zhao X, Rubenstein JL, Hsi ED. Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors. Journal of hematopathology. 2024. PMID: 39549220

Ribrag V, Iglesias L, De Braud F, Ma B, Yokota T, Zander T, Spreafico A, Subbiah V, Illert AL, Tan D, Santoro A, Munster PN, Suehiro Y, Wang Y, Ji DM, Chen S, Beltz K, Suenaga N, Ramkumar T, Luo F, Lai C, Wainberg ZA. A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies. European journal of cancer (Oxford, England : 1990). 2024. PMID: 39793445

Chen LY, Thibaud S, Bodnar S, Chari A, Richter J, Cho HJ, Sanchez LJ, Rodriguez C, Rossi AC, Richard S, Parekh S, Jagannath S. MRD-negative duration following latest line of therapy predicts long-term PFS in real-world multiple myeloma patients. Blood advances. 2024. PMID: 39546749

Geng H, Mo SS, Chen L, Ballapuram A, Tsang M, Lu M, Rauschecker AM, Wen KW, Devine WP, Solomon DA, Rubenstein JL. Identification of Genomic Biomarkers of Disease Progression and Survival in Primary CNS Lymphoma. Blood advances. 2024. PMID: 39536287

Luck C, Jacobs KA, Okimoto RA. The Capicua C1 Domain is Required for Full Activity of the CIC::DUX4 Fusion Oncoprotein. Cancer Research Communications. 2024. PMID: 39530749

Mennillo E, Lotstein ML, Lee G, Johri V, Ekstrand C, Tsui J, Hou J, Leet DE, He JY, Mahadevan U, Eckalbar W, Oh DY, Fragiadakis GK, Kattah MG, Combes AJ. Single-cell spatial transcriptomics of fixed, paraffin-embedded biopsies reveals colitis-associated cell networks. bioRxiv : the preprint server for biology. 2024. PMID: 39605355

Bazhenova L, Kim DW, Cho BC, Goel S, Heist R, Werner TL, Eaton KD, Wang JS, Pant S, Adkins DR, Blakely CM, Yan X, Neuteboom S, Christensen JG, Chao R, Bauer T. Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study. Future oncology (London, England). 2024. PMID: 39513224

Kim J, Munster PN. Estrogens and breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2024. PMID: 39522613

Shah NP. The promise of allosteric kinase inhibition. Blood. 2024. PMID: 39509121

Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies. JCO precision oncology. 2024. PMID: 39509670

Bogdan Popescu, Madison Piao, Sydney Abelson, Carolina E. Morales, Khadija Yousuf, Jose M. Rivera, Cheryl A C Peretz, Elliot Stieglitz, Catherine C. Smith. Preclinical Activity of RAS(ON) Multi-Selective Inhibitor RMC-7977 and Therapeutic Combinations in AML with Signaling Mutations. Blood. 2024. PMID:

Michelle Wang, Krishna V. Komanduri, Debajyoti Datta, Ayan Patel, Barbee Whitaker, Artur Belov, Benjamin Rubin, Rohit Vashisht, Rosa Rodriguez-Monguio, Pelin Cinar, Steven Anderson, Atul Butte. AI Predicts Early Relapse Post-Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma Patients in a Multi-Center Real-World Study. Blood. 2024. PMID:

Jun Ma, Michael P Randall, Ming Lu, Lingjing Chen, Huimin Geng, Aishwarya Kumar, Saloni Malla, Mark Noviski, Ryan Rountree, James L. Rubenstein. BTK Degradation As a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Patient-Derived, Rodent Models. Blood. 2024. PMID:

Michael P Randall, Huimin Geng, Lingjing Chen, Aishwarya Ballapuram, Chitoh Yung, Ming Lu, Gregory Chin, Michael Mish, Jamie Bates, James L. Rubenstein. Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma. Blood. 2024. PMID:

Alvaro J Alencar, Olivia Bobek, Neha Mehta-Shah, Narendranath Epperla, Christine Lu-Emerson, Sarah C. Rutherford, Adam J. Olszewski, Thomas Ollila, Samuel Singer, Travis Dockter, Susan M. Geyer, Lori Rosenstein, Macarena De La Fuente, Eric D. Hsi, Shira N. Dinner, James L. Rubenstein, Nancy L. Bartlett, John P. Leonard. Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL). Blood. 2024. PMID:

Kelly Schoenbeck, Isabelle Vu, Albert Lee, Mansa Devaki, Insiyah Merchant, Faaiz Ibrahim, Anand Dhruva, Catherine C. Smith, Neil P. Shah, Chloe Atreya. Living with CML: A Qualitative Analysis. Blood. 2024. PMID:

Matthew F Jones, Cheryl A C Peretz, Vanessa E. Kennedy, Elaine Tran, Andrew Koh, Andriana Kotini, Malgorzata Olszewska, Eirini Papapetrou, Catherine C. Smith. AML Derived Induced Pluripotent Stem Cells Reveal a Genotype-Independent Effect of Monocytic Differentiation in Mediating Venetoclax Resistance. Blood. 2024. PMID:

Timothy T. Ferng, Samantha M. Pintar, Vanessa E. Kennedy, Shaheen Kabir, Theodore C. Tarver, Veronica Steri, Paul Phojanakong, Juwita Hübner, Carolina E. Morales, Jose M. Rivera, Aaron C. Logan, Benjamin Braun, Elliot Stieglitz, Luke A. Gilbert, Catherine C. Smith. CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition. Blood. 2024. PMID:

Mei R, Pepe E, Oh DY, Tsai KK, Chugh R, Kattah MG. Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab. Inflammatory bowel diseases. 2024. PMID: 39495057